Aleksandar Sekulic
Overview
Explore the profile of Aleksandar Sekulic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassir S, Yousif M, Li X, Severson K, Hughes A, Kechter J, et al.
J Invest Dermatol
. 2025 Jan;
PMID: 39884456
Cutaneous squamous cell carcinoma is one of the most common cancers in humans and kills as many people annually as melanoma. The understanding of the transcriptional changes with respect to...
2.
Bandel L, Vierkant R, Kruisselbrink T, Bublitz M, Wilson T, Armasu S, et al.
Mayo Clin Proc
. 2024 Dec;
PMID: 39625429
Objective: To execute a large-scale, decentralized, clinical-grade whole exome sequencing study, coined Tapestry, for clinical practice, research discovery, and genomic education. Patients And Methods: Between July 1, 2020, and May...
3.
Farina J, Olson R, Dhamija R, Bofferding A, Sekulic A, Egan J, et al.
Genes (Basel)
. 2024 Nov;
15(11).
PMID: 39596629
: Pectus excavatum (PEx) is considered, at least partially, a familial disorder. A variety of inheritance patterns, associations with genetic syndromes, and pathogenic variants have been reported. However, the etiology...
4.
Hughes A, Li X, Lehman J, Nelson S, DiCaudo D, Mudappathi R, et al.
JID Innov
. 2024 Oct;
4(6):100296.
PMID: 39391813
Drug repurposing is an attractive strategy for therapy development, particularly in rare diseases where traditional drug development approaches may be challenging owing to high cost and small numbers of patients....
5.
Stratigos A, Chen C, Ivanescu C, Lewis K, Peris K, Bechter O, et al.
Future Oncol
. 2024 Jul;
20(30):2249-2258.
PMID: 39073799
To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC). Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to...
6.
Peris K, Inocencio T, Stratigos A, Lewis K, Eroglu Z, Chang A, et al.
Cancer Med
. 2024 Jul;
13(14):e7360.
PMID: 39031963
Background: A phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor...
7.
Hwang A, Kechter J, Li X, Hughes A, Severson K, Boudreaux B, et al.
J Invest Dermatol
. 2024 Feb;
144(9):1994-2001.e4.
PMID: 38417541
Necrobiosis lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the Jak1/2 inhibitor, ruxolitnib, in the...
8.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, et al.
J Natl Compr Canc Netw
. 2024 Jan;
22(1D):e240002.
PMID: 38244274
The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines...
9.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1181-1203.
PMID: 37935106
Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates...
10.
Stratigos A, Sekulic A, Peris K, Bechter O, Prey S, Lewis K, et al.
J Am Acad Dermatol
. 2023 Oct;
90(2):414-418.
PMID: 37839734
No abstract available.